BioNTech SE and Pfizer (PFE) recently received a positive recommendation from the European Medicines Agency for marketing ...

Pfizer (PFE) is currently under significant scrutiny due to a study linking its product, Depo-Provera, to increased health risks, and an associated Multi-District Litigation could have influenced its ...

Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX), its partner for the Comirnaty COVID-19 vaccine, made legal submissions to London's Court of Appeal on Thursday seeking to overturn a prior court ruling ...

Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents, in the latest round of a ...

The 2nd U.S. Circuit Court of Appeals ruled in favor of Pfizer (PFE), in a lawsuit by Do No Harm challenging the company's diversity fellowship program. Read more here.

Pfizer and the direct purchasers entered into the settlement agreement Nov. 22. The agreement still needs official court approval. More articles on legal & regulatory issues: ...

The lawsuit specifically seeks to allow Pfizer to reimburse members for heart failure drugs, which would otherwise cost $13,000 in Medicare copays a year, Fortune reported on July 28.

In the latest chapter of the legal saga, Pfizer and BioNTech are pressing the U.S. Patent and Trademark Office (PTO) to invalidate a pair of Moderna patents tied to mRNA vaccine production.

In light of the rapid spread of the delta variant and full FDA approval of the Pfizer COVID-19 vaccine, many employers are either now implementing or considering a vaccine mandate.

Neither Pfizer nor its outside lawyers from Dechert and Paul, Weiss, Rifkind, Wharton & Garrison responded to my email query on the amicus filings. The company has until April 8 to respond to the ...

The group sued Pfizer over the company's Breakthrough Fellowship Program, which the company launched in 2021, arguing the program discriminated against white and Asian-American applicants in ...

Pfizer (PFE) and BioNTech (BNTX) challenge Moderna's patent win in London court over mRNA COVID-19 vaccine technology. Read more here.